kalii chloridum 0,15% + natrii chloridum 0,9% kabi (1,5 mg + 9 mg)/ml roztwór do infuzji
fresenius kabi polska sp. z o.o. - kalii chloridum + natrii chloridum - roztwór do infuzji - (1,5 mg + 9 mg)/ml
kalii chloridum 0,3% + natrii chloridum 0,9% kabi (3 mg + 9 mg)/ml roztwór do infuzji
fresenius kabi polska sp. z o.o. - kalii chloridum + natrii chloridum - roztwór do infuzji - (3 mg + 9 mg)/ml
kalii chloridum 0,15% + glucosum 5% kabi (1,5 mg + 50 mg)/ml roztwór do infuzji
fresenius kabi polska sp. z o.o. - kalii chloridum + glucosaminum - roztwór do infuzji - (1,5 mg + 50 mg)/ml
kalii chloridum 0,3% + glucosum 5% kabi (3 mg + 50 mg)/ml roztwór do infuzji
fresenius kabi polska sp. z o.o. - kalii chloridum + glucosum monohydricum - roztwór do infuzji - (3 mg + 50 mg)/ml
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. potrójnej terapii skojarzonej), jako uzupełnienie diety i ćwiczeń fizycznych u pacjentów niedostatecznie kontrolowanych o ich maksymalnej tolerowanej dawki sulfonylomocznika z metforminą i. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.